
|Videos|January 11, 2016
The Aftermath of Hepatitis C Drugs on Specialty Spending
Author(s)Davy James, Managing Editor
David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.
Advertisement
David Lassen, chief clinical officer at Prime Therapeutics, discusses how high cost hepatitis C drugs have impacted the entire specialty landscape.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Functional Cure of Hepatitis B Infections Among Patients Coinfected With HIV
2
White Bagging, Brown Bagging, and the Pharmacist Caught in the Middle
3
New Climate Model May Help Predict Influenza Outbreaks Worldwide
4
Integrating Suzetrigine Into Acute Pain Care Requires Evidence, Access, and Pharmacist Leadership
5










































































































